These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague. Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643 [TBL] [Abstract][Full Text] [Related]
4. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant. Dinc G; Pennington JM; Yolcu ES; Lawrenz MB; Shirwan H Vaccine; 2014 Sep; 32(39):5035-40. PubMed ID: 25045812 [TBL] [Abstract][Full Text] [Related]
5. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles. Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457 [TBL] [Abstract][Full Text] [Related]
6. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Honko AN; Sriranganathan N; Lees CJ; Mizel SB Infect Immun; 2006 Feb; 74(2):1113-20. PubMed ID: 16428759 [TBL] [Abstract][Full Text] [Related]
7. Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine. Airhart CL; Rohde HN; Hovde CJ; Bohach GA; Deobald CF; Lee SS; Minnich SA Vaccine; 2008 Oct; 26(44):5554-61. PubMed ID: 18722493 [TBL] [Abstract][Full Text] [Related]
8. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague. Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954 [TBL] [Abstract][Full Text] [Related]
9. Complete Protection Against Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W Front Immunol; 2022; 13():793382. PubMed ID: 35154110 [TBL] [Abstract][Full Text] [Related]
10. Induction of Protective Antiplague Immune Responses by Self-Adjuvanting Bionanoparticles Derived from Engineered Yersinia pestis. Wang X; Singh AK; Zhang X; Sun W Infect Immun; 2020 Apr; 88(5):. PubMed ID: 32152195 [TBL] [Abstract][Full Text] [Related]
11. Electroporation of a multivalent DNA vaccine cocktail elicits a protective immune response against anthrax and plague. Albrecht MT; Livingston BD; Pesce JT; Bell MG; Hannaman D; Keane-Myers AM Vaccine; 2012 Jul; 30(32):4872-83. PubMed ID: 22633906 [TBL] [Abstract][Full Text] [Related]
12. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203 [TBL] [Abstract][Full Text] [Related]
13. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity. Eyles JE; Butcher WA; Titball RW; Hill J Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388 [TBL] [Abstract][Full Text] [Related]
15. Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection. Haupt RE; Harberts EM; Kitz RJ; Strohmeier S; Krammer F; Ernst RK; Frieman MB Vaccine; 2021 Aug; 39(36):5205-5213. PubMed ID: 34362603 [TBL] [Abstract][Full Text] [Related]
16. IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection. Lin JS; Kummer LW; Szaba FM; Smiley ST J Immunol; 2011 Feb; 186(3):1675-84. PubMed ID: 21172869 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates. Williamson ED; Flick-Smith HC; Waters E; Miller J; Hodgson I; Le Butt CS; Hill J Microb Pathog; 2007 Jan; 42(1):11-21. PubMed ID: 17107769 [TBL] [Abstract][Full Text] [Related]
18. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague. Elvin SJ; Williamson ED Microb Pathog; 2004 Oct; 37(4):177-84. PubMed ID: 15458778 [TBL] [Abstract][Full Text] [Related]
19. Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice. Uppada SB; Bhat AA; Sah A; Donthamshetty RN Vaccine; 2011 Nov; 29(50):9352-60. PubMed ID: 22001881 [TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine. Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]